title: Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
authors.affiliation: Department of Medical Oncology.
authors.forename: Rob R H
authors.initials: RR
authors.lastname: van den Brom
authors.affiliation: Department of Rheumatology and Clinical Immunology.
authors.forename: Wayel H
authors.initials: WH
authors.lastname: Abdulahad
authors.affiliation: Department of Rheumatology and Clinical Immunology.
authors.forename: Abraham
authors.initials: A
authors.lastname: Rutgers
authors.affiliation: Department of Medical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
authors.forename: Bart-Jan
authors.initials: BJ
authors.lastname: Kroesen
authors.affiliation: Department of Medical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
authors.forename: Caroline
authors.initials: C
authors.lastname: Roozendaal
authors.affiliation: Department of Medical Oncology.
authors.forename: Derk Jan A
authors.initials: DJ
authors.lastname: de Groot
authors.affiliation: Department of Medical Oncology.
authors.forename: Carolien P
authors.initials: CP
authors.lastname: Schröder
authors.affiliation: Department of Medical Oncology.
authors.forename: Geke A P
authors.initials: GA
authors.lastname: Hospers
authors.affiliation: Department of Rheumatology and Clinical Immunology e.brouwer@umcg.nl.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Brouwer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000139:chemically induced*; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; C582435:pembrolizumab